Search

Prospective, Multicenter Clinical Impact Evaluation of a 31-Gene Expression Profile Test for Management of Melanoma Patients

Page 111-121

A Survey Based Study on the Sun Safety Knowledge of Students Attending Public Schools in San Antonio, TX

Page 31-33

Establishing an evidence-based decision point for clinical use of the 31-gene expression profile test in cutaneous melanoma

Page 239-249

Appropriate Use Criteria for the Integration of Diagnostic and Prognostic Gene Expression Profile Assays into the Management of Cutaneous Malignant Melanoma: An Expert Panel Consensus-Based Modified Delphi Process Assessment

Page 291-306

Clinical Reliability and Reproducibility of a Prognostic 31-Gene Expression Profile Test for Cutaneous Melanoma, and Association of the Test with Standard Clinicopathologic Factors

Page s106

Assessment of the 31-Gene Expression Profile Test by Dermatologists: A Cross-Sectional Survey from National Dermatology Conferences

Page 101-107

Development and Validation of a Diagnostic 35-Gene Expression Profile Test for Ambiguous or Difficult-to-Diagnose Suspicious Pigmented Skin Lesions

Page 506-522

The Comparative Effects of Various Moisturizers on Epidermal Barrier Function Recovery After Bathing in Atopic Dermatitis.

Page 219-223

SkinSpecs: A Mobile Solution that Addresses an Unmet Need for Tracking Chronic Skin Diseases in the Office and at Home

Page 309-320

Risk Stratification of Severely Dysplastic Nevi by Non-Invasively Obtained Gene Expression and Mutation Analyses

Page 124-129

Biologic Prescribing Patterns Among Mount Sinai Psoriasis Patients: Results of a Retrospective Chart Review

Page 106-111

A 35-Gene Expression Profile Test for use in Suspicious Pigmented Lesions Impacts Clinical Management Decisions of Dermatopathologists and Dermatologists

Page 523-533

Interim Analysis of Survival Outcomes in a Prospective Multicenter Cohort Evaluating a Prognostic 31-Gene Expression Profile (GEP) Test for Melanoma

Page s110

Clinical Impact of a 31-Gene Expression Profile Test on Physician Recommendations for Management of Melanoma Patients in a Prospectively Tested Cohort

Page s107

An Adhesive Patch Biopsy Based Gene Expression Test to Non-invasively Differentiate Basal Cell and Squamous Cell Carcinomas from Actinic Keratoses and Other Skin Lesions of Similar Appearance

Page s111

Health Econommic Implications of a Non-Invasive Gene Expression Test for Primary Cutaneous Melanoma

Page s109

Findings from a large US registry study to assess the real-world utility of a non-invasive gene expression test designed to rule out primary cutaneous melanoma

Page S52

Caring for Melanoma Survivors with Self-Detected Concerning Moles During COVID-19 Restricted Physician Access: a Cohort Study

Page 248-251

Dermatology Residency Applicants’ Concerns Due to COVID-19

Page 393-398

Utility of Food Patch Testing in the Evaluation and Management of Irritable Bowel Syndrome

Page 96-110

Aseptic Syphilitic Meningitis in an HIV-Negative Patient with Concomitant Primary and Secondary Syphilis

Page 361-364

Real-world experience and clinical utility of a non-invasive gene expression rule-out test for melanoma and additional validation against high risk driver mutations in BRAF, NRAS and the TERT promoter

Page S69

A Cross-Sectional Study on Herpes Zoster Diagnosis in the time of COVID-19

Page 556-558

A Retrospective Case Series to Evaluate the Clinical Utility of a 31-Gene Expression Profile Test in Cutaneous Melanoma Patients

Page S44

A Randomized, Parallel Group, Open Label, Multicenter Study to Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing with Clobetasol Propionate Cream (Impoyz™), 0.025% versus Clobetasol Propionate (Temovate®)